Business and Data Analysis
PHSI uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSI model and assess its impact on your financial results.
View our case studies related to business and data analysis:
Accounting Firm Required Pharmacy Expertise
Client Selects Copay Reduction Program
Determining Competitive Market Landscape
Drug Resources Made Available via Manufacturer’s Website
Generic Competition Studied to Determine Effects on Brand Drug
Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource
Manufacturer Seeks Pre-Launch Rebate Level Forecasting
Medicare PDP Develops Community Pharmacy MTM Program
PBM Contract Variance Analysis
PBM Positions Itself for Increased Rebate Yield
PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy
PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care
Proactive Response to Loss of Brand Patent Protection
Rebate Contracting Consolidation Process Directed by PHSI
Research Updates Brand Designation in Drug Databases
Poll Results
November 2018 Question of the Month
Do you believe there are sufficient treatment options for HIV to warrant formulary exclusions?
Yes: 75%
No: 25%
Do you believe there are sufficient treatment options for Hemophilia to warrant formulary exclusions?
Yes: 71%
No: 29%
Do you believe there are sufficient treatment options for Hereditary Angioedema to warrant formulary exclusions?
Yes: 17%
No: 83%
October 2018 Question of the Month
How will state regulation and licensure of PBMs impact retail pharmacies? (select all that apply)
Improve pharmacy reimbursement rates: 5.88%
Add transparency to Rx reimbursement: 35.29%
Reduce PBM conflict of interests: 17.65%
Eliminate retrospective financial clawbacks: 17.65%
No impact: 11.76%
Reduce pharmacy reimbursement rates: 11.76%
September 2018 Question of the Month
How will the addition of step therapy on Medicare Part B drugs impact biosimilars?
Increase use of biosimilars: 54.55%
No Change: 36.36%
Decrease biosimilar use: 9.09%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
